J.P. Morgan analyst Seiji Wakao maintained a Hold rating on PHC Holdings Corp. (2GY – Research Report) yesterday and set a price target of ...

IHH Healthcare said on Thursday its unit submitted an expert report to a Tokyo court which states damages sought from Japan's ...

DelveInsight's Peptide-drug Conjugate Market Insights report provides the current and forecast market analysis, individual ...

A global pharmaceutical company partnered with DelveInsight to create a robust and simplified solution enabling its top ...

Japanese healthcare firm Daiichi Sankyo Co., Ltd (DSKYF.PK) announced Friday the appointment of Hiroyuki Okuzawa as Chief Executive ...

(RTTNews) - The U.S. Food and Drug Administration has approved AstraZeneca Plc. (AZN.L, AZN) and Daiichi Sankyo's (DSKYF.PK) ENHERTU (fam-trastuzumab deruxtecan-nxki) for the treatment of adult ...

Of course, some criticize these modern logos as being copy-and-paste, minimalist and unoriginal. Those yearn to return to the unique logos of the 1990s and early 2000s, where the NFL used elements ...

However, the asset faced a series of setbacks in 2024. The FDA on Friday approved AstraZeneca and Daiichi Sankyo’s Dato-DXd, to be known as Datroway, for patients with certain advanced breast ...

Datroway will cost nearly $4,900 per vial, Reuters reported. The treatment will hit U.S. shelves in approximately two weeks, according to Daiichi Sankyo’s announcement of the approval. In a note to ...

Tokyo: D aichi Sankyo has announced that DATROWAY (datopotamab deruxtecan-dlnk) has been approved in the U.S. for the treatment of adult patients with unresectable or metastatic hormone receptor (HR) ...